
|Articles|June 1, 2002
Targeted therapies inhibit PCa bone metastasis
San Francisco-Prostate cancer bone metastases appear to react favorablyto treatment with a new bisphosphonate and the tyrosine-kinase inhibitorsPKI-166 and STI-571, according to studies presented at the American Associationfor Cancer Research annual meeting here.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
2
Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC
3
Study suggests potential diuretic effect with nadofaragene firadenovec
4
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
5











